Patent application number | Description | Published |
20100303902 | SELF-EMULSIFYING PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN - The invention relates to self emulsifying drug delivery system based compositions of rhein or diacerein, or salts or esters or prodrugs thereof which are bioequivalent to a 50 mg diacerein formulation marketed under the trade name Art 50®. The compositions exhibit no variability in fed and fasted state conditions. The compositions also result in significant reduction in side effects such as, soft stools effects as compared to Art 50®. The invention also relates to methods for preparing such compositions. | 12-02-2010 |
20110052681 | Pharmaceutical compositions of entacapone co-micronized with sugar alcohols - The present invention relates to pharmaceutical compositions comprising entacapone or pharmaceutically acceptable salts thereof along with one or more sugar alcohols; wherein the entacapone is co-micronized with one or more sugar alcohols. The invention also relates to processes of making such compositions. | 03-03-2011 |
20110091558 | Pharmaceutical Compositions of Entacapone, Levodopa and Carbidopa with Improved Bioavailability - The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapon, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone, levodopa and carbidopa combination formulation marketed under the trade name Stalcvo200®. The invention also relates to processes for making such compositions. | 04-21-2011 |
20110229561 | Extended Release Pharmaceutical Composition Of Entacapone Or Salts Thereof - There is provided an extended release pharmaceutical composition comprising from about 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also provides an extended release pharmaceutical composition comprising triple combination of from about 30 mg to about 300 mg of levodopa, 10 mg to about 100 mg of carbidopa and 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions. | 09-22-2011 |
20110229566 | Single Unit Oral Dose Pharmaceutical Composition Comprising Levodopa, Carbidopa And Entacapone Or Salts Thereof - There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions. | 09-22-2011 |
20140187644 | Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability - The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapone, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone, levodopa and carbidopa combination formulation marketed under the trade name Stalevo200®. The invention also relates to processes for making such compositions. | 07-03-2014 |
Patent application number | Description | Published |
20090111788 | ANTIBIOTIC COMPOSITIONS OF MODIFIED RELEASE AND PROCESS OF PRODUCTION THEREOF - Novel modified release pharmaceutical compositions wherein the composition comprises at least one antibiotic(s) preferably amoxicillin or its pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof either alone or in combination with other antibiotic(s) as active ingredient, with at least one release modifying agent(s) for controlling the release of the beta lactam antibiotic optionally with one or more other pharmaceutically acceptable excipient(s) is provided, wherein the dosage form provides a release of not more than about 60% of the antibiotic in about 30 minutes and not less than about 70% of the antibiotic after 8 hours when subjected to in vitro dissolution study or when tested in vivo. Further, the compositions of the present invention which when tested in a group of healthy humans provide a mean peak plasma concentration (C | 04-30-2009 |
20100204333 | Novel Pharmaceutical Modified Release Dosage Form Cyclooxygenase Enzyme Inhibitor - Pharmaceutical modified release dosage form comprising at least one cyclooxygenase enzyme inhibitor or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof as active agent, with a pharmaceutically acceptable carrier for controlling the release of the cyclooxygenase enzyme inhibitor is provided. The dosage form preferably provides a release of not more than about 60% of the cyclooxygenase enzyme inhibitor in 1 hour and not less than about 75% of the cyclooxygenase enzyme inhibitor after 12 hours when tested in accordance with the dissolution method (I) described herein employing Distilled water with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (II) described herein employing pH 7.0 Phosphate buffer with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (III) described herein employing 0.001 N Hydrochloric acid with 1.0% Sodium lauryl sulphate as dissolution medium. Further, the pharmaceutical composition of the present invention when tested in a group of healthy humans preferably achieves a mean peak plasma concentration (C | 08-12-2010 |
Patent application number | Description | Published |
20090288146 | SECURE CENTRALIZED BACKUP USING LOCALLY DERIVED AUTHENTICATION MODEL - A system and method for performing backup operations is provided. Mechanisms facilitate a secure centralized backup system with a locally derived authentication model. A local centralized storage server may generate an authentication model, including credentials, and create a share/directory for each client. Clients store their credentials and use them to access centralized storage. Credentials are maintained and provisioned locally. A remote host server may establish trust by providing a list of clients in a circle. | 11-19-2009 |
20090310165 | AUTOMATIC DETECTION AND RECONFIGURATION OF DEVICES - Described is a technology by which movement of a shared network device (e.g., a printer or storage device) to a different network machine triggers an automatic reconfiguration of the device and/or the network machines, so that those machines remain able to share that device. Configuration data may be pushed to the network machines, pulled by the network machines, and/or provided to a server by which the network machines may access the confirmation data. Reconfiguration may include creating a system user account and modifying the permissions associated with the device so that the other machine has access permission to use the device via the created account. | 12-17-2009 |
20120150548 | BUSINESS APPLICATION LIFECYCLE MANAGEMENT - The subject disclosure relates to lifecycle management for business models associated with a business application as well as implementations of the business models. As described herein, a framework is provided in which business models can be built using modeling tools. The framework defines a separation of models from implementations and their relationships. Support is provided for translation of a business model to an implementation automatically and/or manually using development tools. Further embodiments herein define relationships of models to their implementations at various levels of granularity. Relationships can be defined and maintained at various granularity levels of a business application with different addressable granularity of an implemented application. These relationship associations can be used as described herein for tracking and managing changes in an implementation that may affect an associated model and vice versa. | 06-14-2012 |
20120159133 | BUSINESS EXCEPTION MANAGEMENT PATTERN FOR BUSINESS PROCESSES - Handling business process exceptions. A method includes a computing system using a template, causing one or more operations to be performed to determine a problem that caused a business process exception. The computing system uses a template to cause one or more operations to be performed to perform one or more repair operations to address the business process exception. The computing system uses a template, to cause one or more operations to be performed to take action on the business process exception. | 06-21-2012 |
20130097198 | BUSINESS ACTIVITY MONITORING RUNTIME - Systems and methods for monitoring business applications are disclosed. Data is provided from an application programming interface (API) in a monitored application to a collection runtime. The collection runtime collects data based upon a data collection model. A current time increment is assigned to the collected data. The collected data is provided as a stream of event data to an event processing service, which performs one or more queries on the data stream. The results of the queries are provided to a data store and/or to a user interface. The data collection model is created from a data collection profile, and the queries are created from an observation model. | 04-18-2013 |
20130148165 | Automatic Detection and Reconfiguration of Devices - Described is a technology by which movement of a shared network device (e.g., a printer or storage device) to a different network machine triggers an automatic reconfiguration of the device and/or the network machines, so that those machines remain able to share that device. Configuration data may be pushed to the network machines, pulled by the network machines, and/or provided to a server by which the network machines may access the confirmation data. Reconfiguration may include creating a system user account and modifying the permissions associated with the device so that the other machine has access permission to use the device via the created account. | 06-13-2013 |